Unlocking Blood Cancer: How Epigenetic Profiles Enhance Diagnosis and Treatment

Recent research in biomedical laboratories has shifted from traditional methods to innovative approaches using computer technology. Scientists now often analyze molecular and cellular databases before conducting experiments. This advancement includes contributions from computer scientists and mathematicians.

Dr. Esteller’s team has created a significant database that details the epigenetic profiles of a wide collection of cultured blood, bone marrow, and lymph node cells. They examined over 800,000 sites of DNA modification, including samples from both humans and mice. These findings provide valuable insights for researchers in basic, applied, and clinical fields.

Dr. Esteller highlights that the epigenomes they studied closely resemble those in patients’ primary tumors. This means the database can assist in diagnosing blood cancers when there is uncertainty about their classification. They have already successfully applied this method to brain tumors and sarcomas.

The research also analyzed drug sensitivity for over 300 medications. They developed a separate algorithm to predict which epigenetic changes indicate sensitivity or resistance to these drugs. This will support clinical research, helping identify tumors of unknown origin and informing treatment decisions.

The data from this study is publicly available online, providing a valuable resource for researchers. The study received funding from the Spanish and Catalan governments, the Cellex Foundation, “La Caixa” Foundation, and the Spanish Association Against Cancer (AECC).

For more information, read the research published in the journal Leukemia (Noguera-Castells, A., et al. 2024). Access the study: doi.org/10.1038/s41375-024-02478-2.